Cover Image
市場調查報告書

血吸蟲症:開發平台分析

Schistosomiasis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 251629
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
血吸蟲症:開發平台分析 Schistosomiasis - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 40 Pages
簡介

血吸蟲症是棲息在河川或湖泊等淡水之寄生蟲造成的感染症之一。症狀有高燒、頭痛、咳嗽、造成深紅色發炎的皮膚炎、腹痛、關節痛、肌肉疼痛等。

本報告提供血吸蟲症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 調查範圍

血吸蟲症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;S比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • BioDiem Ltd
  • Concert Pharmaceuticals, Inc.
  • Kancera AB
  • LondonPharma Ltd
  • Merck KGaA

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BDM-I
  • D-Praziquantel
  • 腸血吸蟲症 疫苗
  • L-Praziquantel
  • 血吸蟲症用小分子

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9737IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schistosomiasis - Pipeline Review, H2 2017, provides an overview of the Schistosomiasis (Infectious Disease) pipeline landscape.

Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes. Symptoms include a high temperature, headache, cough, a dark red, blotchy, raised skin rash, pain in the abdomen and joint and muscle pain.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schistosomiasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Schistosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schistosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Schistosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schistosomiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Schistosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schistosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schistosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schistosomiasis (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schistosomiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schistosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Schistosomiasis - Overview
    • Schistosomiasis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Schistosomiasis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Schistosomiasis - Companies Involved in Therapeutics Development
    • Kancera AB
    • Knight Therapeutics Inc
    • LondonPharma Ltd
    • Merck KGaA
    • Salvensis
  • Schistosomiasis - Drug Profiles
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDE-1102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • intestinal schistosomiasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • intestinal schistosomiasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-Praziquantel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • miltefosine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-praziquantel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • schistosomiasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Schistosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Schistosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Schistosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Schistosomiasis - Dormant Projects
  • Schistosomiasis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 23, 2013: BioDiem US patent for skin and wound infections
      • Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites
      • Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I
      • Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I
      • Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Schistosomiasis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Schistosomiasis - Pipeline by Kancera AB, H2 2017
  • Schistosomiasis - Pipeline by Knight Therapeutics Inc, H2 2017
  • Schistosomiasis - Pipeline by LondonPharma Ltd, H2 2017
  • Schistosomiasis - Pipeline by Merck KGaA, H2 2017
  • Schistosomiasis - Pipeline by Salvensis, H2 2017
  • Schistosomiasis - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Schistosomiasis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top